# ADC Therapeutics (ADCT) — Earnings

ADCT · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/adct/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.11 |
| EPS estimate | −$0.22 |
| EPS surprise | +49.07% |
| Revenue surprise | +1.91% |
| Revenue | $19.2M |
| Revenue estimate | $18.9M |
| Reported | Aug 13, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1771910/000162828026056711/adc-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/1d60f060-a5a6-3332-5e8b-29bd6e6036d0.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 13, 2026 | −$0.22 | −$0.11 | 49.07% | $18.9M | $19.2M |
| Q1 2026 | May 4, 2026 | −$0.20 | −$0.21 | -4.12% | $20.0M | $20.9M |
| Q4 2025 | Mar 10, 2026 | −$0.27 | −$0.04 | 85.09% | $22.3M | $23.1M |
| Q3 2025 | Nov 10, 2025 | −$0.36 | −$0.30 | 17.42% | $16.8M | $16.4M |
| Q2 2025 | Aug 12, 2025 | −$0.49 | −$0.50 | -1.63% | $17.9M | $18.8M |
| Q1 2025 | May 14, 2025 | −$0.40 | −$0.36 | 10.74% | $17.7M | $23.0M |
| Q4 2024 | Mar 27, 2025 | −$0.41 | −$0.29 | 29.56% | $19.0M | $16.9M |
| Q3 2024 | Nov 7, 2024 | −$0.40 | −$0.42 | -6.33% | $18.4M | $18.5M |
| Q2 2024 | Aug 6, 2024 | −$0.46 | −$0.38 | 16.89% | $18.9M | $17.4M |
| Q1 2024 | May 6, 2024 | −$0.56 | −$0.56 | -0.76% | $18.0M | $18.1M |
| Q4 2023 | Mar 13, 2024 | −$0.50 | −$1.03 | -105.14% | $15.3M | $16.8M |
| Q3 2023 | Nov 7, 2023 | −$0.63 | −$0.58 | 8.52% | $15.2M | $14.5M |
| Q2 2023 | Aug 8, 2023 | −$0.70 | −$0.58 | 17.10% | $20.2M | $19.3M |
| Q1 2023 | May 9, 2023 | −$0.02 | −$0.74 | -3600.00% | $20.1M | $19.0M |
| Q4 2022 | Feb 28, 2023 | −$0.48 | −$0.30 | 37.93% | $39.4M | $69.8M |
| Q3 2022 | Nov 8, 2022 | −$0.35 | −$0.65 | -84.19% | $60.7M | $76.3M |
| Q2 2022 | Aug 9, 2022 | −$0.80 | −$0.84 | -5.22% | $31.2M | $17.3M |
| Q1 2022 | May 9, 2022 | −$0.67 | −$0.22 | 67.33% | $37.1M | $46.5M |
| Q4 2021 | Mar 3, 2022 | −$0.85 | −$0.45 | 46.79% | $16.5M | $17.0M |
| Q3 2021 | Nov 2, 2021 | −$0.92 | −$0.93 | -1.41% | $7.4M | $13.1M |

## Frequently Asked Questions

### When did ADC Therapeutics (ADCT) last report earnings?

ADC Therapeutics last reported on Aug 13, 2026, covering fiscal Q2 2026.

### Did ADCT beat earnings estimates?

Yes. ADC Therapeutics reported EPS of −$0.11 for Q2 2026 against a −$0.22 estimate — a 49.07% beat.

### How much revenue did ADCT report last quarter?

ADC Therapeutics reported $19.2M in revenue for Q2 2026, against a consensus estimate of $18.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).